Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney cancer drug combo under the microscope in Real-World study

NCT ID NCT03647878

Knowledge-focused Sponsor: Ipsen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 7 times

Summary

This study observes 224 adults with advanced or metastatic kidney cancer who are taking cabozantinib alone or with nivolumab as their first treatment. Researchers track how often doses are reduced, paused, or stopped due to side effects in everyday medical practice. The goal is to understand real-world safety and dosing patterns, not to test new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cabozantinib and nivolumab
What this could lead to
If successful, this study could help doctors better manage side effects and dosing for kidney cancer patients on these drugs.
What could go wrong
This is an observational study, not a treatment trial, so it won't test if the drugs work better than other options. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

224 people

The number who actually took part.

Started

Sep 2018

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated with Cabozantinib as monotherapy or in combination with nivolumab in advanced or metastatic renal cell carcinoma in 1st line treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females aged 18 years and older with capacity to consent. * Subjects receiving cabozantinib as monotherapy or in combination with nivolumab as a first line treatment for advanced or metastatic renal cell carcinoma * Subjects with the intention to be treated with cabozantinib tablets as monotherapy or in combination with nivolumab according to the current local Summary of Product Characteristics (SmPC); decision has to be taken before entry in the study. * Signed written informed consent Exclusion Criteria: * Participation in an interventional study at the same time and/or within 3 months before baseline. * Previous participation in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced renal cell carcinoma Metastatic renal cell carcinoma

Contacts and locations

Locations

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Brüderkrankenhaus St. Josef Paderborn

    Paderborn, 33098, Germany

  • Centrum für Operative Urologie

    Bremen, 28277, Germany

  • Edia.med MVZ

    Chemnitz, 09130, Germany

  • Elblandklinikum Riesa

    Riesa, 01589, Germany

  • Evangelisches Krankenhaus Hamm gGmbH

    Hamm, 59063, Germany

  • Facharztpraxis für Hämatologie und Internistische Onkologie

    München, 80331, Germany

  • Fachzentrum für Urologie Eggenfelden

    Eggenfelden, Germany

  • Franziskus Hospital Bielefeld

    Bielefeld, 33615, Germany

  • GFO Kliniken Rhein-Berg

    Bergisch Gladbach, Germany

  • GIM - Gemeinschaftspraxis Innere Medizin

    Witten, 58455, Germany

  • Gemeinschaftspraxis

    Garbsen, 30823, Germany

  • Gemeinschaftspraxis Hämatologie-Onkologie, Dresden

    Dresden, Germany

  • Gemeinschaftspraxis für Urologie Cottbus

    Cottbus, Germany

  • Hämatologisch-Onkologische Schwerpunktpraxis

    Bad Liebenwerda, Germany

  • Immunologisch onkologisches MVZ

    Hanover, 30449, Germany

  • Kepler Universitätsklinikum GmbH

    Linz, 4021, Austria

  • Kliniken Maria Hilf GmbH

    Mönchengladbach, 41063, Germany

  • Klinikum Bremen Mitte

    Bremen, Germany

  • Klinikum Nürnberg

    Nuremberg, 90419, Germany

  • Klinikum Osnabrück GmbH

    Osnabrück, Germany

  • Klinikum Sindelfingen-Böblingen

    Sindelfingen, 71065, Germany

  • Klinikum Solingen

    Solingen, Germany

  • Klinikum Wels-Grieskirchen GmbH

    Wels, 4600, Austria

  • Klinikum am Bruderwald Medizinische Klinik V

    Bamberg, 96049, Germany

  • Krankenhaus Barmherzige Brüder Regensburg

    Regensburg, Germany

  • Krankenhaus Martha-Maria Halle-Dölau

    Halle, Germany

  • Krankenhaus Torgau J. Kentmann gGmbH

    Torgau, Germany

  • Krankenhaus der Barmherzigen Brüder Trier

    Trier, 54292, Germany

  • Kreiskliniken Herford

    Herford, Germany

  • LMU Urologische Klinik und Poliklinik

    München, Germany

  • Landeskrankenhaus Hochsteiermark

    Leoben, A-8700, Austria

  • MVZ Kreis Olpe

    Olpe, 57462, Germany

  • MVZ MP Saaletal

    Saalfeld, 07318, Germany

  • MVZ Taunus GmbH

    Bad Homburg, Germany

  • MVZ Urologie gGmbH

    Nuremberg, Germany

  • Markuskrankenhaus

    Frankfurt am Main, Germany

  • Medizinische Studiengesellschaft Nord-West GmbH

    Westerstede, 26655, Germany

  • Onkologie am Segelfliegerdamm

    Berlin, 12487, Germany

  • Onkologie aschaffenburg

    Aschaffenburg, 63739, Germany

  • Onkologische Praxis Moers

    Moers, 47441, Germany

  • Onkologische Schwerpunktpraxis

    Kronach, Germany

  • Onkologisches Studienzentrum am Raschplatz

    Hanover, 30161, Germany

  • Onkologisches Zentrum Donauwörth

    Donauwörth, 86609, Germany

  • Onkozentrum Dresden/Freiberg

    Dresden, 01127, Germany

  • Praxis Naunhof

    Naunhof, Germany

  • Praxis Urologie Köpenick

    Berlin, Germany

  • Praxis Urologie Köpenick

    Zwickau, Germany

  • Praxis am Volkspark

    Berlin, Germany

  • Praxis für Hämatologie und Internistische Onkologie

    Neustadt am Rübenberge, 31535, Germany

  • Praxis für Hämatologie, Onkologie und Gerinnung

    Kronach, 96317, Germany

  • Praxis für Urologie

    Berlin, 12099, Germany

  • Praxis für Urologie, Andrologie, Onkologie und medikamentöse Tumortherapie

    Markkleeberg, 04416, Germany

  • Praxisgemeinschaft für Onkologie und Urologie

    Wilhelmshaven, 26389, Germany

  • Salzkammergutklinikum Vöcklabruck

    Vöcklabruck, A-4840, Austria

  • Sana Klinikum Offenbach GmbH

    Offenbach, Germany

  • St. Georg Klinikum

    Eisenach, 99817, Germany

  • Studienzentrum UnterEms

    Leer, Germany

  • Uniklinik Jena

    Jena, Germany

  • Uniklinik Marburg

    Marburg, Germany

  • Uniklinikum Erlangen

    Erlangen, Germany

  • Uniklinikum Salzburg

    Salzburg, A-5020, Austria

  • Universitätsklinikum Aachen

    Aachen, Germany

  • Universitätsklinikum Augsburg A.ö.R

    Augsburg, 86156, Germany

  • Universitätsklinikum Gießen und Marburg GmbH

    Giessen, Germany

  • Universitätsklinikum Magdeburg

    Magdeburg, 39120, Germany

  • Universitätsklinikum Münster

    Münster, 48149, Germany

  • Universitätsmedizin Göttingen

    Göttingen, 37075, Germany

  • Urologie

    Potsdam, Germany

  • Urologische Arztpraxis

    Bernburg, Germany

  • Urologische Arztpraxis

    Eisleben Lutherstadt, 06295, Germany

  • Urologische Arztpraxis

    Leipzig, Germany

  • Urologische Gemeinschaftspraxis

    Dresden, 01307, Germany

  • Urologische Gemeinschaftspraxis

    Neunkirchen, 66538, Germany

  • Urologische Praxis

    Luckenwalde, Germany

  • Urologische Praxis

    Parchim, 19370, Germany

  • Urologische Praxis Bad Schlema

    Bad Schlema, Germany

  • Urologische Praxis Berlin

    Berlin, Germany

  • Urologisches Zentrum Euregio

    Aachen, Germany

  • Vivantes Klinikum am Urban

    Berlin, Germany

  • Zentrum für Ambulante Onkologie

    Schorndorf, 73614, Germany

  • Zentrum für urologische Onkologie, Palliativmedizin und allgemeine Urologie

    Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.